A randomized, double-blind, placebo-controlied trial of subcutaneous etanercept (p75 souble tumor necrosis factor: FC fusion protein) in the treatment of moderate to severe Crohns’ disease

Posted on July 15, 2015 by William J. Sandborn, Stephen B. Hanauer, Seymour Katz, Michael Safdi, Daouglas C. Wolf, Richard D. Baerg, William J. Tremaine, Therese Johnson, Nancy Diehl, Alan R. Zinsmeister
This entry was posted in Uncategorized. Bookmark the permalink.